Newsroom
Moderna, Inc. (MRNA) Faces Securities Lawsuit: Investors Encouraged to Take Action
By KlickAnalytics Data Insights | September 5, 2024 08:04PM ET
Key Points
- Levi & Korsinsky, Rosen Law Firm, Schall Law Firm, Pomerantz Law Firm, and Bronstein, Gewirtz & Grossman, LLC all announce class action lawsuits against Moderna, Inc.
- Investors who suffered losses in Moderna, Inc. between January 18, 2023, and June 25, 2024, are encouraged to contact legal firms before the October 8, 2024 deadline.
- Moderna, Inc. faces allegations of violations of federal securities laws, prompting legal action against the company.
- European Medicines Agency recommends authorization of Moderna's updated COVID-19 vaccine for the 2024-2025 vaccination season.
- Shareholders of Moderna, Inc. are urged to seek potential recovery under the federal securities laws through legal representation.
Several prominent law firms, including Levi & Korsinsky, Rosen Law Firm, Schall Law Firm, Pomerantz Law Firm, and Bronstein, Gewirtz & Grossman, LLC, have recently announced class action lawsuits against Moderna, Inc. These lawsuits come following allegations of violations of federal securities laws by the pharmaceutical company.
Investors who experienced losses in Moderna, Inc. between January 18, 2023, and June 25, 2024, are strongly encouraged to reach out to these legal firms before the upcoming deadline of October 8, 2024. The lawsuits aim to seek damages on behalf of individuals and entities who purchased or acquired Moderna securities during the specified "Class Period."
In a notable development, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Moderna's updated COVID-19 vaccine Spikevax. This revised vaccine is designed to target the SARS-CoV-2 variant JN.1 and will be utilized for active immunization against COVID-19 in individuals aged six months and older.
Following the positive opinion from the CHMP, the European Commission is set to make a decision on authorizing Moderna's updated COVID-19 vaccine for the autumn/winter season of 2024-2025. This decision holds significant implications for the availability and distribution of the vaccine across Europe.
Shareholders who have been impacted by financial losses in Moderna, Inc. are advised to take action and explore potential avenues for recovery under the federal securities laws. By engaging with legal representatives from the aforementioned firms, investors can navigate the complexities of the securities class action lawsuits and seek redress for any damages incurred.
As the legal proceedings unfold and the authorization decision for Moderna's updated COVID-19 vaccine approaches, the situation surrounding Moderna, Inc. continues to evolve. Investors are urged to stay informed and proactive in safeguarding their rights and interests in response to these developments.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with